16 September 2026 editorial review · Item
Anti-IL-21 antibody + liraglutide: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: new record; substantive review 16 September 2026.
- Scope and findings: Added a historical discontinued programme. Checked the randomized Phase 2 abstract, registry and Novo Q3 2020 discontinuation announcement, plus FDA orphan status. Uses 308 randomized, not an asserted 308-person treated analysis denominator. Benefit at 54 weeks and deterioration off treatment remain distinct.
- Primary sources checked: Anti-IL-21 antibody and liraglutide in recent-onset T1D: randomized Phase 2 trial (peer-reviewed); NCT02443155 — study record (registry); Novo Nordisk Q3 2020 financial report: combination development discontinued (manufacturer); FDA orphan designation record for NNC0114-0006 plus liraglutide (regulatory).
- Limits: Paper abstract supports numerical claims; full patient-level data were not reanalyzed. Regulatory-path discontinuation is not relabeled as efficacy failure. No active programme or current treatment access claimed.